238 related articles for article (PubMed ID: 16116930)
1. Effect of alendronate on bone mineral density in Puerto Rican males with osteoporosis.
Martinó A; Rosa J; Guzmán J; Ramírez M
P R Health Sci J; 2005 Jun; 24(2):131-5. PubMed ID: 16116930
[TBL] [Abstract][Full Text] [Related]
2. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
Skordis N; Ioannou YS; Kyriakou A; Savva SC; Efstathiou E; Savvides I; Christou S
Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
[TBL] [Abstract][Full Text] [Related]
3. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
[TBL] [Abstract][Full Text] [Related]
4. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
5. Active comparator trial of teriparatide vs alendronate for treating glucocorticoid-induced osteoporosis: results from the Hispanic and non-Hispanic cohorts.
Losada BR; Zanchetta JR; Zerbini C; Molina JF; De la Peña P; Liu CC; Smith RB; Nino AJ; Krohn K; Warner MR
J Clin Densitom; 2009; 12(1):63-70. PubMed ID: 19028124
[TBL] [Abstract][Full Text] [Related]
6. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
Bonnick S; Broy S; Kaiser F; Teutsch C; Rosenberg E; DeLucca P; Melton M
Curr Med Res Opin; 2007 Jun; 23(6):1341-9. PubMed ID: 17594775
[TBL] [Abstract][Full Text] [Related]
7. Effects of alendronate on bone mineral density in men with prostate cancer treated with androgen deprivation therapy.
Bruder JM; Ma JZ; Wing N; Basler J; Katselnik D
J Clin Densitom; 2006; 9(4):431-7. PubMed ID: 17097529
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Marques-Neto JF; Weryha G; Verbruggen N; Hustad CM; Mahlis EM; Melton ME
Int J Clin Pract; 2008 Apr; 62(4):575-84. PubMed ID: 18324951
[TBL] [Abstract][Full Text] [Related]
9. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
10. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
11. [Clinic effect of alendronate sodium treatment in osteoporosis patients with hip fracture].
Qiu GX; Wu ZH; Shen JX; Luo XZ; Tang H; Wang YP; Weng XS; Yang XY; Lin J; Jin J; Zhao H; Tian Y; Zhang JG
Zhonghua Wai Ke Za Zhi; 2004 Mar; 42(6):347-50. PubMed ID: 15144688
[TBL] [Abstract][Full Text] [Related]
12. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
Guven Z; Karadag-Saygi E; Unlu-Ozkan F; Akyuz G
Aging Male; 2007 Dec; 10(4):197-201. PubMed ID: 18033629
[TBL] [Abstract][Full Text] [Related]
13. Effects of alendronate on bone density in men with primary and secondary osteoporosis.
Ho YV; Frauman AG; Thomson W; Seeman E
Osteoporos Int; 2000; 11(2):98-101. PubMed ID: 10793867
[TBL] [Abstract][Full Text] [Related]
14. Effect of alendronate on bone mineral density in adult patients with Laron syndrome (primary growth hormone insensitivity).
Eshed V; Benbassat CA; Laron Z
Growth Horm IGF Res; 2006 Apr; 16(2):119-24. PubMed ID: 16617031
[TBL] [Abstract][Full Text] [Related]
15. [Alendronate prevents steroid-induced osteoporosis in patients with rheumatic diseases].
Wang QH; Wu HX; Huang YL; Xue J; Yang XY; Zhu L; Wen LH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1888-91. PubMed ID: 19040000
[TBL] [Abstract][Full Text] [Related]
16. Selective estrogen receptor modulators: A possible new treatment of osteoporosis in males.
Kastelan D; Giljevic Z; Kraljevic I; Korsic M
Med Hypotheses; 2006; 67(5):1052-3. PubMed ID: 16790322
[TBL] [Abstract][Full Text] [Related]
17. [Prediction of changes in bone density during alendronate treatment in postmenopausal women].
Masaryk P; Stancíková M; Letkovská A; Rovenský J
Vnitr Lek; 2002 Oct; 48(10):943-7. PubMed ID: 16737141
[TBL] [Abstract][Full Text] [Related]
18. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
19. The prevention of bone fractures after liver transplantation: experience with alendronate treatment.
Atamaz F; Hepguler S; Karasu Z; Kilic M; Tokat Y
Transplant Proc; 2006 Jun; 38(5):1448-52. PubMed ID: 16797329
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates are effective prophylactic of early bone loss after renal transplantation.
Nowacka-Cieciura E; Cieciura T; Baczkowska T; Kozińska-Przybył O; Tronina O; Chudziński W; Pacholczyk M; Durlik M
Transplant Proc; 2006; 38(1):165-7. PubMed ID: 16504693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
